List of Excipients in Branded Drug NINTEDANIB ESYLATE

Generic Drugs Containing NINTEDANIB ESYLATE

Company	Ingredient	NDC	Excipient
Macleods Pharmaceuticals Limited	nintedanib esylate	33342-550	AMMONIA
Macleods Pharmaceuticals Limited	nintedanib esylate	33342-550	CAPRYLOCAPROYL POLYOXYLGLYCERIDES 8
Macleods Pharmaceuticals Limited	nintedanib esylate	33342-550	FERRIC OXIDE RED
Macleods Pharmaceuticals Limited	nintedanib esylate	33342-550	FERRIC OXIDE YELLOW
Macleods Pharmaceuticals Limited	nintedanib esylate	33342-550	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in NINTEDANIB ESYLATE?

# Of NDCs	Excipient
1	AMMONIA
1	CAPRYLOCAPROYL POLYOXYLGLYCERIDES 8
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE

# Nintedanib Esylate Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Nintedanib esylate is a poorly water-soluble kinase inhibitor marketed primarily as Ofev soft capsules by Boehringer Ingelheim. The commercial formulation relies on a lipid-based fill rather than a conventional aqueous or immediate-release tablet system. The strongest excipient opportunities are in lipid formulation optimization, softgel manufacturing, bioequivalent generic development, dose-flexible pediatric products, and differentiated formulations that reduce food effects or gastrointestinal intolerance.

Nintedanib is approved in the United States for idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases with a progressive phenotype, and systemic sclerosis-associated interstitial lung disease. The labeled doses are 150 mg twice daily, with a 100 mg twice-daily dose used when tolerability or hepatic safety requires reduction.[1]

What excipients are used in Ofev nintedanib capsules?

The Ofev dosage form is a liquid-filled soft gelatin capsule. Its excipient system is designed to solubilize or disperse nintedanib esylate, maintain dose uniformity, and support absorption of a lipophilic active pharmaceutical ingredient.

Ofev formulation architecture

Public labeling identifies the principal formulation components as:

Formulation element	Reported or functionally relevant materials	Primary role
Lipid vehicle	Medium-chain triglycerides or related triglyceride excipients	Solubilization and dispersion
Consistency agent	Hard fat	Controls fill viscosity and capsule stability
Wetting or emulsifying agent	Lecithin	Improves dispersion and interfacial behavior
Capsule shell	Gelatin and glycerol	Forms the softgel shell
Opacifier and colorants	Titanium dioxide and iron oxides	Appearance, light protection and product identification

The exact excipient composition can vary by market and manufacturing site. The U.S. prescribing information lists the inactive ingredients and capsule-shell components for the marketed strengths.[1]

Nintedanib esylate is the ethanesulfonate salt of nintedanib. The labeled 100 mg and 150 mg strengths are expressed as nintedanib, not as the total esylate salt. The corresponding salt quantities are approximately 120.4 mg and 180.6 mg, respectively, assuming the marketed stoichiometric salt form.

Why the lipid vehicle matters

Nintedanib has limited aqueous solubility. A lipid vehicle can reduce dependence on gastrointestinal dissolution and improve the reproducibility of absorption. The formulation also provides a practical route to a high-dose small molecule without requiring a large tablet or multiple-unit solid dosage form.

The excipient system must balance several properties:

• Drug loading and fill volume
• Chemical stability of nintedanib esylate
• Physical stability during storage
• Softgel shell compatibility
• Capsule leakage resistance
• Digestive tolerability
• Fed and fasted pharmacokinetic performance
• Manufacturing speed and fill-weight control

The marketed product is taken with food. The label reports that food increases exposure and delays absorption relative to administration under fasted conditions.[1] This creates a technical opportunity for formulations that reduce food-dependent pharmacokinetic variability.

How should an excipient strategy for nintedanib esylate be designed?

A commercial development program should begin with a lipid-based platform because the reference product has already established that route. A solid oral alternative may be commercially attractive, but it carries a higher bioequivalence and formulation risk.

Lipid formulation strategy

A rational screening program should compare:

1. Medium-chain triglycerides
2. Long-chain triglycerides
3. Mixed mono- and diglycerides
4. Hard-fat or hydrogenated lipid systems
5. Phospholipid-containing vehicles
6. Self-emulsifying drug delivery systems
7. Surfactant-assisted lipid formulations

The critical tests are not limited to equilibrium solubility. The development package should measure:

• Drug solubility in the excipient matrix
• Precipitation after aqueous dilution
• Dispersion performance in biorelevant media
• Lipolysis behavior
• Capsule-shell interaction
• Peroxide and oxidative impurity formation
• Fill viscosity across temperature ranges
• Long-term and accelerated stability

A self-emulsifying formulation could improve dispersion in gastrointestinal fluid, but surfactant concentration must be controlled. Excess surfactant can increase gastrointestinal adverse events, which is commercially important because diarrhea, nausea and vomiting are common nintedanib-related tolerability issues.[1]

Solid dispersion strategy

An amorphous solid dispersion could support a tablet or hard capsule product. Candidate polymers include hypromellose, hydroxypropyl cellulose, copovidone and related precipitation-inhibiting materials. Spray drying, hot-melt extrusion and solvent evaporation are possible manufacturing routes.

The main risks are:

• Recrystallization of nintedanib
• Salt dissociation
• Residual solvent control
• High polymer burden
• Lower drug loading than the reference softgel
• Food-effect changes
• Failure to reproduce the reference product’s absorption profile

A solid dispersion is more likely to create a differentiated product than a simple excipient substitution. It may also support a tablet, sprinkle capsule or multiparticulate dosage form. That differentiation can create new intellectual-property positions, but it raises clinical and regulatory complexity.

Cyclodextrin and complexation approaches

Cyclodextrins may improve apparent aqueous solubility, but their commercial value is less certain than that of lipid vehicles or solid dispersions. The amount of complexing agent needed, the potential for altered release and the impact on capsule or tablet size must be assessed early.

Complexation is most attractive if it produces one of the following outcomes:

• A low-volume aqueous formulation
• A pediatric liquid or dispersible dosage form
• A formulation with reduced food effect
• Improved dose proportionality at lower strengths

What formulation patents could protect nintedanib products?

Formulation patents can protect the excipient system, manufacturing process, dosage form and performance characteristics. For nintedanib, the most commercially relevant claim categories are likely to include:

Claim category	Potential protected subject matter
Lipid composition	Specific triglyceride, hard-fat, phospholipid or surfactant ratios
Softgel fill	Drug concentration, viscosity range and capsule-shell compatibility
Solid dispersion	Polymer identity, drug-to-polymer ratio and process conditions
Multiparticulates	Pellet size, coating composition and release profile
Pediatric dosage form	Taste masking, dispersibility and dose flexibility
Pharmacokinetic performance	Reduced food effect or specified exposure range
Manufacturing process	Mixing, deaeration, encapsulation and drying conditions
Stability	Control of degradation products or salt conversion

A patent built only around the use of common excipients is vulnerable if the claims do not require a narrow composition or measurable performance limitation. Stronger protection generally combines composition limits with manufacturing parameters and pharmacokinetic or dissolution results.

Patentability may be improved by demonstrating an unexpected result, such as:

• Lower interpatient exposure variability
• Reduced precipitation after dispersion
• Lower gastrointestinal intolerance
• Improved shell stability
• Smaller capsule size
• Equivalent exposure under fed and fasted conditions
• Better stability at elevated temperature and humidity

When does nintedanib lose exclusivity?

Nintedanib exclusivity is fragmented across compound, formulation, method-of-use and regulatory rights. The compound’s earliest patent rights do not necessarily determine the commercial launch date for all indications.

U.S. regulatory timeline

Milestone	Date
FDA approval of Ofev for idiopathic pulmonary fibrosis	October 2014
FDA approval for chronic fibrosing ILD with a progressive phenotype	July 2019
FDA approval for systemic sclerosis-associated ILD	September 2020
Pediatric labeling expansion	FDA labeling should be assessed against the current product record

Nintedanib is not a biologic, so biosimilar regulation does not apply. A competing product would generally proceed through the abbreviated new drug application pathway if it can demonstrate pharmaceutical equivalence and bioequivalence to the listed reference product.

The practical loss-of-exclusivity date depends on the active Orange Book listings, patent-term adjustments, pediatric exclusivity, litigation outcomes and any enforceable settlement terms. Exact launch timing cannot be inferred from the original Ofev approval date alone.

What is the Orange Book status of Ofev?

Ofev is an FDA-approved small-molecule product. Its relevant regulatory questions are:

• Which patents are listed for the approved dosage forms?
• Which patents cover the active ingredient, formulation or method of use?
• Which listed patents have expired?
• Are any patents subject to pediatric exclusivity?
• Have ANDA applicants filed Paragraph IV certifications?
• Has FDA approved any ANDA for nintedanib?

An ANDA applicant may certify that a listed patent is invalid, unenforceable or will not be infringed. A Paragraph IV notice can trigger patent litigation and, depending on timing, a 30-month stay of ANDA approval under the Hatch-Waxman framework.[2]

The critical commercial distinction is between a patent that blocks approval and a patent that only creates litigation risk. A method-of-use patent may not block a carve-out product if the generic label omits the patented indication and the remaining labeling does not encourage the infringing use.

Which companies are challenging nintedanib exclusivity?

Nintedanib competition is more likely to emerge from generic pharmaceutical companies than from biosimilar developers. The most credible entrants will have:

• Softgel encapsulation capacity
• Experience with lipid-filled dosage forms
• Access to nintedanib esylate active ingredient
• Bioequivalence expertise for food-sensitive products
• A regulatory strategy for multiple indications
• Capacity to manage capsule-shell and fill-material qualification

A generic company can pursue a formulation close to Ofev or develop a different formulation that satisfies the reference-product requirements. A materially different formulation may reduce dependence on the reference excipient system, but it may also increase clinical, analytical and litigation risk.

Publicly confirmed company-by-company Paragraph IV activity should be evaluated from FDA ANDA litigation records and federal court filings rather than inferred from development announcements. No biologic biosimilar pathway is relevant.

What generic entry risks exist for Ofev?

The main generic-entry risk is formulation complexity, not active-ingredient synthesis alone.

Technical barriers

A generic manufacturer must control:

• Nintedanib esylate particle characteristics
• Drug loading in the lipid fill
• Fill-weight uniformity
• Capsule-shell moisture
• Dissolution or dispersion behavior
• Degradation products
• Food-effect sensitivity
• Bioequivalence under fed and fasted conditions

The product’s gastrointestinal tolerability also creates a practical risk. A formulation that produces a sharper concentration peak or greater exposure variability may be pharmacokinetically acceptable in a narrow study but commercially less acceptable to prescribers and patients.

Regulatory barriers

FDA may require comparative dissolution, bioequivalence under fed and fasted conditions, and evidence that the generic has the same dosage form, strength, route of administration and active ingredient as the reference product. A softgel-to-tablet switch can be more difficult than a softgel-to-softgel approach because the dosage form and absorption mechanism differ.

A 100 mg strength is commercially important. It is used for dose reduction and may have particular value for patients with hepatic impairment or adverse events. A generic portfolio that launches only the 150 mg strength would have a narrower substitution profile.

What commercial opportunities exist for new nintedanib formulations?

Pediatric and dose-flexible products

A liquid, dispersible, sprinkle or mini-tablet presentation could support pediatric use and dose titration. The formulation must address:

• Taste masking
• Low-dose uniformity
• Administration through soft food or liquid
• Stability after reconstitution
• Accurate dose measurement
• Compatibility with enteral feeding devices

Dose flexibility may also benefit adults who require step-down dosing because of diarrhea, nausea or hepatic laboratory abnormalities.

Reduced food-effect formulations

A formulation that produces comparable exposure under fed and fasted conditions could improve convenience and reduce administration variability. Such a product would need strong pharmacokinetic evidence and careful labeling analysis. It could be protected through composition claims combined with fed-versus-fasted performance claims.

Improved gastrointestinal tolerability

A formulation that slows dissolution, reduces peak concentration or alters intestinal dispersion could potentially reduce gastrointestinal adverse events. The commercial value is substantial because tolerability affects persistence with therapy. A slower-release formulation, however, could alter efficacy and may require clinical bridging rather than a conventional bioequivalence-only strategy.

Regional temperature stability

Lipid-filled softgels can face stability challenges in hot and humid markets. Opportunities include:

• Higher oxidation resistance
• Improved foil packaging
• Lower-temperature manufacturing
• Reduced capsule-shell brittleness
• Better in-use stability
• Heat-stable solid formulations

Packaging and excipient improvements may be commercially valuable even when they do not create a new dosage form. They can reduce distribution losses and support emerging-market expansion.

Contract manufacturing and excipient supply

Commercial opportunities extend beyond finished-dose products. Suppliers can compete in:

• Pharmaceutical-grade medium-chain triglycerides
• Hard-fat systems
• Lecithin and phospholipid blends
• Softgel shell materials
• Low-peroxide lipid excipients
• Specialized encapsulation equipment
• Analytical methods for lipid formulations
• Spray-dried dispersion platforms

The most defensible supplier position is a qualified, validated excipient system with demonstrated compatibility with nintedanib esylate, rather than a commodity excipient sold without formulation data.

How does nintedanib compare with competing pulmonary fibrosis drugs?

Product	Active ingredient	Dosage form	Main formulation issue	Competitive implication
Ofev	Nintedanib esylate	Lipid-filled softgel	Solubility, food effect and GI tolerability	Strong opportunity for softgel and dose-flexible alternatives
Esbriet	Pirfenidone	Tablets and capsules	High pill burden and tolerability	Nintedanib formulation improvements can compete on convenience and persistence
Generic pirfenidone	Pirfenidone	Tablets or capsules	Manufacturing scale and substitution	Price competition may pressure nintedanib after generic entry
Investigational antifibrotics	Various	Varies	Product-specific	New mechanisms could reduce dependence on formulation differentiation

Nintedanib’s formulation strategy differs from pirfenidone because the commercial product depends more directly on lipid-mediated solubilization. This increases manufacturing complexity but creates more room for excipient-driven differentiation.

What is the revenue exposure to nintedanib formulation competition?

Ofev is a major commercial product for Boehringer Ingelheim, with demand linked to chronic treatment of pulmonary fibrosis and related interstitial lung diseases. Revenue exposure to generic entry is material because patients generally require long-term therapy, and the indications have expanded beyond idiopathic pulmonary fibrosis.

The commercial impact of generic entry will depend on:

• Timing of the first approved ANDA
• Number of launch competitors
• Whether 100 mg and 150 mg strengths launch together
• Generic substitution rules by state and market
• Availability of authorized generic supply
• Persistence of method-of-use patents
• Payer pressure and specialty-pharmacy contracting
• Physician acceptance of non-reference lipid formulations

A differentiated formulation with pediatric utility, better tolerability or reduced food effect could preserve value after basic small-molecule exclusivity declines. A purely interchangeable softgel would compete primarily on price, supply reliability and payer access.

How strong is the nintedanib patent estate?

The patent estate should be assessed in four layers:

1. Composition-of-matter rights for nintedanib or related kinase-inhibitor structures.
2. Salt, polymorph and crystalline-form rights covering nintedanib esylate.
3. Formulation and manufacturing rights covering the softgel or lipid system.
4. Method-of-use rights covering pulmonary fibrosis and other diseases.

The commercial strength of the estate is highest when multiple layers overlap and when later-expiring formulation or method patents remain enforceable. The estate is weaker if protection depends mainly on an expired compound patent or if the listed patents are vulnerable to invalidity, noninfringement or label carve-out arguments.

Nintedanib has no biosimilar barrier. Its principal protection challenge is the ability of generic manufacturers to reproduce exposure from a lipid-filled reference product while avoiding valid listed patents.

Key Takeaways

• Nintedanib esylate is best suited to lipid-based formulation development because of limited aqueous solubility.
• Ofev uses a liquid-filled softgel system built around triglyceride, hard-fat and lecithin-type excipients.
• The highest-value formulation opportunities are reduced food effect, improved gastrointestinal tolerability, pediatric dosing and regional stability.
• Generic development is technically more difficult than conventional tablet substitution because of softgel manufacture and food-sensitive pharmacokinetics.
• Formulation patents should combine narrow composition limits with manufacturing parameters and demonstrated pharmacokinetic or stability advantages.
• Nintedanib is a small molecule, so biosimilar risk is irrelevant; ANDA and Paragraph IV activity are the primary U.S. competition pathways.
• The 100 mg dose is commercially important because it supports dose reduction and tolerability management.
• Excipient suppliers and CDMOs can compete through validated lipid systems, low-peroxide materials and softgel process capability.

FAQs

Can nintedanib esylate be formulated as a tablet?

Yes. A tablet could use an amorphous solid dispersion, lipid-based powder, spray-dried intermediate or other solubility-enhancement technology. The key risk is matching the reference product’s exposure under fed and fasted conditions.

Which excipients are most important for nintedanib softgels?

Medium-chain triglycerides, hard fat and lecithin are central to the lipid fill. Gelatin and glycerol are important for the capsule shell, while titanium dioxide and iron oxides support opacity and identification.

Is nintedanib esylate suitable for a liquid formulation?

Potentially, but a liquid product would need to address chemical stability, precipitation, taste, dose uniformity and storage after opening. A lipid suspension or self-emulsifying liquid may be more practical than a simple aqueous solution.

Can an excipient change create new patent protection?

Yes. A new excipient ratio, processing method or dosage form may support patent claims if it produces a novel and non-obvious composition or a measurable technical advantage. Routine substitution of common excipients is less defensible.

Does nintedanib have biosimilar competition?

No. Nintedanib esylate is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, including ANDA filings and potential Paragraph IV litigation, rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Ofev (nintedanib) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. European Medicines Agency. (2014). Vargatef: EPAR product information. European Medicines Agency.

4. U.S. Food and Drug Administration. (2019). FDA approves first treatment for chronic, progressive forms of interstitial lung diseases. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2020). FDA approves Ofev for systemic sclerosis-associated interstitial lung disease. U.S. Department of Health and Human Services.